Introduction
Bone remodeling is a complex process regulated by hormones and growth factors (1) . Hormones are known to have important effects on bone metabolism and have been studied extensively, but recent work has revealed that growth factors also have significant effects on bone function. Growth factors are polypeptides that increase cell replication and have important effects on differentiated cell function. Initially growth factors were considered to act as systemic agents, but current evidence indicates that they act primarily as local regulators of cell growth. Individual growth factors are synthesized by multiple tissues and cell types and may act on cells of the same class (autocrine factors) or on different cells (paracrine factors). Growth factors have been studied primarily in vitro and their exact role is still somewhat unclear, but their effects on cell replication and differentiation are pronounced and are likely of physiological significance.
Recent work has revealed that bone cells synthesize a number of growth factors and that the bone matrix is a rich source of these polypeptides (2) (3) (4) . Experimental data indicate that the two major processes of bone remodeling, bone formation and resorption, are closely regulated and that local factors play a critical role in their control. It is suspected that these factors mediate the effects of systemic hormones, which could modify the synthesis or effects of the local factors. Bone is a heterogeneous tissue comprised of a mixed cell population and is in direct contact with cartilage and marrow cells; therefore, the local regulators of bone remodeling may originate from a variety of cells. While true local regulators of bone metabolism are synthesized by skeletal cells, the bone matrix may trap systemic factors that could act as putative local regulators of bone remodeling. These issues were taken into consideration when classifying the local regulators of skeletal growth into (a) growth factors synthesized by skeletal cells; (b) growth factors isolated from bone matrix; and (c) growth factors synthesized by cells from adjoining tissues (Table I) .
GROWTH FACTORS SYNTHESIZED BY SKELETAL CELLS
Studies performed by us and other investigators have shown that cultured bones and bone cells synthesize a transforming growth factor of the ,3 class, a bone-derived growth factor (BDGF),1 insulin-like growth factor (IGF), or somatomedin (Sm) C, and platelet-derived growth factor (2, 5-7). These factors have significant effects on bone remodeling, but neither their synthesis nor their influence on cell metabolism are limited to the skeletal tissue.
Transforming growth factor (TGF) f TGFs are polypeptides isolated from normal and neoplastic tissues and are known to alter normal cell growth (8 Sm C Sm C or IGF I is a growth hormone-dependent polypeptide that stimulates cartilage growth. There have been a number of Sm's described, but only two have been characterized: IGF I and IGF II. IGF I has a molecular weight of 7,600 and is synthesized by multiple tissues, including bone and cartilage, but the synthesis of IGF II by skeletal cells has not been reported (6, 13, 14) . Since multiple tissues synthesize Sm C, the function of the circulating hormone is uncertain, particularly since the systemic administration of Sm C has only a marginal effect on cartilage growth. This observation supports the concept that local Sm has a major role as a regulator ofgrowth (6) . Detailed studies on the hormonal regulation of Sm C synthesis by skeletal cells have not been reported, but growth hormone stimulates Sm C synthesis in a variety oftissues and possibly in bone (13, 14) .
Cultures of rat calvariae were recently found to synthesize a Sm C and to secrete one or more Sm-binding proteins (6) . In bone cultures, Sm C stimulates the replication of preosteoblastic cells; consequently, it increases the number of osteoblasts capable of synthesizing bone matrix (15) . Sm C also has a direct stimulatory effect on osteoblastic differentiated function that is independent from that on cell replication; thus, Sm C stimulates bone matrix synthesis by two different mechanisms. Sm C has no effect on bone resorption. Since (2 m and Sm C have similar effects on skeletal tissue and since (2 m is known to modulate the effects of other hormones on cell function, one may speculate that (32 m plays a role in the regulation ofthe action ofthe locally produced Sm C on skeletal metabolism. Other molecules suspected of modulating the availability or effects of Sm C on bone cell function are Sm-binding proteins ( 16) . These proteins are considered to have a number of functions including the transport of Sm, prolongation of its half-life, and modulation of Sm activity, but their exact function in the skeletal tissue has not been established.
Platelet-derived growth factor (PDGF) PDGF is a two-chain polypeptide with an Mr of 27,000-30,000 (17) . The FGFs aFGF is a member of a family of polypeptides that includes endothelial cell growth factor (ECGF) and eye-derived growth factor II (19, 20) . Two forms of ECGF have been reported: ECGFa, with an Mr of 17,000, and ECGFf3, with an Mr of 20,000. ECGF,3 is a precursor of ECGFa, which itself has a six amino acid extension at the amino terminus when compared with aFGF. The three forms of the factor have similar biological and immunoreactive properties, and since the bone-derived material has not been fully characterized, it is not known which form(s) of the factor is present in bone matrix. bFGF, a 146 amino acid protein with a molecular weight of 16,000, has significant amino acid sequence homology with aFGF, but the two factors are products of different genes (20, 21) . Both factors were initially isolated from the central nervous system, but subsequent investigations revealed that multiple tissues synthesize aFGF and bFGF (22) . bFGF and aFGF bind to the same receptor and have similar biological activities, and are best known for their effects on endothelial cell replication and neovascularization (23) . In bone cultures, both forms of FGF stimulate DNA synthesis and cell replication; this results in an increased bone cell population capable of synthesizing collagen and noncollagen protein (24, 25) . The FGF effect is not specific for collagen, but the collagen synthesized is type I, indicating that at least some of the cells affected are of the osteoblastic lineage. Although FGFs increase the number of osteoblastic cells, they have no direct stimulatory effect on the differentiated function of these cells; in fact, under some conditions, they directly inhibit osteoblastic function (25) .
The stimulatory effects of aFGF and bFGF on neovascularization in association with those on bone cell replication may be important for wound healing and bone repair after fractures. The mitogenic effect of aFGF on endothelial and bone cells is enhanced by heparin, and the fracture callus is rich in heparin-containing mast cells (24) . Heparin increases the binding of aFGF to its receptor, and this could have physiological implications in the process of bone repair, particularly if mast cell degranulation and heparin release occur at the fracture site. The role of FGFs on wound healing is further supported by the fact that these factors are not secreted cell products and may become available only after cell injury or death (18 (i) Monokines. IL-1, tumor necrosis factor a (TNFa), macrophage-derived growth factors, and PDGF are monokines shown to have effects on skeletal tissue.
IL-I
IL-l, a polypeptide with an M, of 17,000-18,000, has an important role in mechanisms of host defense and inflammatory response (27). IL-1, initially described as lymphocyte-activating factor, stimulates the production of IL-2 (T cell growth factor), which enhances T lymphocyte proliferation. IL-1 is not exclusively secreted by the monocyte/macrophage and its effects are not specific for cells of the immune system, since it induces the mitogenesis of several cell types. IL-1 exists in two forms, la and I#; they have different isoelectric points, but partial amino acid homology and similar biological activities.
IL-1 has complex effects on bone remodeling while other interleukins do not have effects on bone formation or bone resorption. IL-1 stimulates bone resorption and is now known to be a component of the activity originally termed osteoclastactivating factor (28) . In addition, IL-1 stimulates cell replication in bone cultures, and at low doses stimulates bone collagen synthesis (29), an effect that is independent from that on bone cell replication. In contrast to these stimulatory effects, exposure of bone cultures to high doses or to prolonged treatment with IL-1 causes a decrease in net collagen production. This may be related to a decrease in collagen synthesis or to an increase in collagen degradation. TNFa TNFa, also known as cachectin, is a monokine with a molecular weight of 17,000 that is produced by activated macrophages (32) . Although TNFa is primarily known for its cytostatic, cytolytic, and antiviral effects, recent work has indicated that TNFa is important in a variety of normal cellular responses. TNFa has a role in events associated with immune response and, in contrast to its growth inhibitory properties on a num-ber of tumor cells, it stimulates the growth of some nontransformed cells. TNFa stimulates bone resorption and bone cell replication (33, 34). The cells that replicate are capable of synthesizing bone collagen, indicating that TNFa affects cells of the osteoblastic lineage. This stimulatory effect on bone collagen is observed after transient treatment with TNFa, and is secondary to its mitogenic effect. In contrast, TNFa causes a direct inhibitory effect on osteoblastic collagen synthesis. The physiological role of TNFa is uncertain since it is a product of the activated macrophage. On the other hand, the (time dependent) dual stimulatory and inhibitory effect of TNFa on bone formation is intriguing and should be taken into consideration when deciding the frequency of its administration when used on clinical trials for its anti-tumor effects. TNFa stimulates IL-1 production by the macrophage, and if this occurred in bone, IL-1 could mediate some ofthe TNFa effects on skeletal remodeling. This is possible since each polypeptide stimulates bone resorption and bone cell replication; the differences in their effects on bone collagen synthesis support the existence of additional mechanisms.
In addition to IL-1 and TNFa, the macrophage secretes other polypeptides with effects on bone remodeling in vitro, such as macrophage-derived growth factor and a PDGF-like molecule (35) .
(ii) Lymphokines. Effects on bone remodeling have also been reported for lymphotoxin and interferon y (IFNy).
Lymphotoxin
Lymphotoxin or TNF,3, a lymphokine secreted by mitogenstimulated lymphocytes, has a molecular weight of 18,600 and has cytotoxic and cytolytic properties for malignant cells. The biological activities of lymphotoxin and TNFa are very similar, and the two peptides share significant amino acid homology in their structure (36) . The effects of lymphotoxin on bone formation and resorption are identical to those of TNFa (34) . The similarity in their effects may be expected since both factors bind to the same receptor with equal affinity. IL-1, TNFa, and lymphotoxin stimulate bone resorption and appear to mediate the hypercalcemia and osteopenia observed with some malignant tumors. However, the physiological role of these factors has not been defined, particularly since they are primarily products of activated mononuclear and lymphoid cells.
IFNy
IFNy is a glycoprotein with anti-viral and antiproliferative activities produced by activated lymphocytes. INFy inhibits collagen synthesis and resorption in bone cultures, and these effects appear secondary to its antiproliferative activities. The inhibitory effects of INF-y are not limited to bone cultures, and it is unlikely that, under normal conditions, it exerts a regulatory influence on bone cell function. However, its effects may be of clinical significance when used in the treatment of malignant tumors.
In summary, bone remodeling is a complex process regulated by systemic hormones and local factors. The exact role of growth factors has not been defined, but it is apparent that factors such as the FGFs stimulate preosteoblast cell replication, which results in an increased osteoblast population capable of synthesizing bone matrix. Other factors, such as IGF I and TGF,B, stimulate cell replication and differentiated function, whereas 2 m and binding proteins probably affect the availability of a factor and the binding to its receptor. It is suspected that the local factors are important in the coupling of bone formation to bone resorption, but their exact mode of action has not been defined. Lymphokines and monokines stimulate bone resorption and preosteoblast cell replication, suggesting a possible role in coupling, but their effects may be more relevant to pathological than to physiological events. The local growth factors found in bone are not unique, suggesting lack of specificity for skeletal tissue. The specificity for this tissue may depend upon the particular cellular event modulated, the state of cell differentiation, the combination of factors to which cells are exposed, the sequence of factor exposure, and their interactions with hormones. Future work should address these issues and determine if systemic hormones enhance or inhibit the synthesis oflocal factors or modulate their activities, as it was recently shown for PTH. Additional research is needed to understand the exact processes affected by the various factors, their mechanism of action, and their effects in vivo.
Although our knowledge about local regulators of skeletal growth is still limited, it is likely that future investigations will reveal that they have an important role in bone remodeling and in the pathogenesis of metabolic bone disease.
